Chargement en cours...
The impact of early phase price agreements on prices of orphan drugs
BACKGROUND: Innovative orphan drugs often have an incremental cost-effectiveness ratio (ICER) which is higher than the maximum threshold for reimbursement. Payers have limited budgets and often cannot pay the full price of a new product, but pharmaceutical and biotechnology companies require a minim...
Enregistré dans:
| Publié dans: | BMC Health Serv Res |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7953706/ https://ncbi.nlm.nih.gov/pubmed/33711994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12913-021-06208-7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|